Who is behind Genovo?
Shows documented founders, leaders, board members, funders and owners.
Not who made decisions, or why.
A connection is not evidence of wrongdoing.
On the record
Sourced links that no one presents as their own account, as recorded so far. Others may exist.
Founded by
-
James M. Wilson
founded
1992
Scholarship & press
12
He denied in 1999 that money drove his research and said the financial relationship was fully explained on the consent form.
Owners
-
James M. Wilson
owns a stake in
Scholarship & press
23
A Harvard course case study, citing Robert Steinbrook (2008) and the Wall Street Journal of 10 August 2000, says Wilson and his family held 30 percent, non-voting. We could not open either source. A 2017 scholarly article says only that he was allowed to control up to 30 percent of the stock. No relative is named in any source we read.
-
University of Pennsylvania
owns a stake in
Scholarship & press
24
A scholarly article says that in 1995 Penn waived part of its conflict-of-interest guidelines, which had given Genovo exclusive rights to license patents from Wilson's lab. A Harvard course case study says Penn's conflict committee reviewed his ties in 1994 and did not seek to end them. Penn denied that money played any part in the trial.
Proof 4 sources
-
Gene study at Penn under fire, The Daily Pennsylvanian, Nov 1999.
Scholarship & press
Wilson founded a private gene-therapy company called Genovo in 1992
-
Ethical Considerations in Phase I studies: Gelsinger Case, HarvardX (Harvard T.H. Chan School of Public Health), course case study.
Scholarship & press
Prior to his move to UPenn, Dr. Wilson had founded Genovo Inc., which had the rights to market his discoveries related to gene transfer
Dr. Wilson and his family had a 30% nonvoting equity stake in Genovo
UPenn had a 3.2% equity stake
-
Death but one unintended consequence of gene-therapy trial, CMAJ, 2001.
Scholarship & press
Wilson, director of the Penn institute where Gelsinger was treated, owned stock in a company, Genovo, that provided financing for the institute.
-
Penn hit by gene therapy lawsuit, The Daily Pennsylvanian, 19 Sep 2000.
Scholarship & press
The University was given shares of the company
How this answer is built
Lines on the record come first: sourced links that no one presents as their own account, each with its strongest source. Then every account recorded here gets its own column, A to Z, none ranked above another. A column quotes only that account's own words and shows the strength of its own sources. Disputed lines are listed apart, with the reason, and lines still being verified come last. Neither is counted. Withdrawn lines are never shown.
When a list is longer than the page shows, the links the public methodology ranks strongest stay (methodology 0.3), and the rest open in the explorer.
Know a source we are missing? Propose it with a pull request to content/entities/org/ge/genovo.md.